January 15th 2021, 10:30pm
Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.
January 15th 2021, 5:00pm
Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.
January 9th 2021, 9:15pm
Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.
January 9th 2021, 1:00am
A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.
December 30th 2020, 4:30pm
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.
December 28th 2020, 3:00pm
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
December 26th 2020, 2:30pm
Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.
December 24th 2020, 4:00pm
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.
December 18th 2020, 6:30pm
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.
December 16th 2020, 7:30pm
Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.
